|
|
|
|
@ -9,11 +9,15 @@ I think I can get two, maybe three, papers out of this:
|
|
|
|
|
|
|
|
|
|
- How can one statistically describe the way drugs pass through the FDA development pipeline?
|
|
|
|
|
- What is the effect of `policy` on phase completion and phase transition?
|
|
|
|
|
- What is the impact of surragate endpoints on phase transition completion? on phase transition?
|
|
|
|
|
|
|
|
|
|
# Models
|
|
|
|
|
|
|
|
|
|
## Phase completion: Joint Probability Estimation (single paper?)
|
|
|
|
|
|
|
|
|
|
This is just following in the footsteps of [[AbrantesMetz-Adams-and-Metz]], but with a possibly different probability estimation approach.
|
|
|
|
|
Also, I think I can improve the richness of the terminal states.
|
|
|
|
|
|
|
|
|
|
Can probably use the data we have.
|
|
|
|
|
This would include Plan Normalized duration, where we take the planned completion date and
|
|
|
|
|
estimate the term: (Actual completion date - start date)/(Planned completion date - start date)
|
|
|
|
|
@ -42,8 +46,31 @@ It would also be straightforward to develop simulations from this approach, as t
|
|
|
|
|
|
|
|
|
|
# Estimation Strategy
|
|
|
|
|
Probably use a non-parametric bayesian approach to estimating the probability densities?
|
|
|
|
|
[AbrantesMetz-Adams-and-Metz] use a hazards model.
|
|
|
|
|
|
|
|
|
|
## Phase Completion Probabilities:
|
|
|
|
|
|
|
|
|
|
The goal is to estimate
|
|
|
|
|
|
|
|
|
|
- P(completing phase 1 & duration phase 1 | Data)
|
|
|
|
|
- P(completing phase 2 & duration phase 2 | Data & transitioned to phase 2 & duration phase 1)
|
|
|
|
|
- P(completing phase 3 & duration phase 3 | Data & transitioned to phase 3 & durations phases 1,2)
|
|
|
|
|
|
|
|
|
|
I may also include the combined phases
|
|
|
|
|
|
|
|
|
|
- P(completing combined phase 1-2 & duration phase 1-2 | Data)
|
|
|
|
|
- P(completing combined phase 2-2 & duration phase 2-3 | Data & transitioned to phase 2 & duration phase 1)
|
|
|
|
|
|
|
|
|
|
## Phase Transition Probabilities:
|
|
|
|
|
|
|
|
|
|
The goal is to estimate
|
|
|
|
|
|
|
|
|
|
- P(transitioning to phase 2 | completing phase 1 & duration phase 1 & Data & market data)
|
|
|
|
|
- P(transitioning to combined phases 2-3 | completing phase 1 & duration phase 1 & Data & market data)
|
|
|
|
|
- P(transitioning to phase 3 | completing phase 2 & durations phases 1,2 & Data & market data)
|
|
|
|
|
- P(transitioning to phase 3 | completing combined phase 1-2 & durations phase 1-2 & Data & market data)
|
|
|
|
|
|
|
|
|
|
## Identification Strategy
|
|
|
|
|
## Identification Strategies
|
|
|
|
|
|
|
|
|
|
### Descriptive identification
|
|
|
|
|
|
|
|
|
|
|